Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

of additional higher doses of LX2931 as an orally-delivered treatment for rheumatoid arthritis," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "While we were disappointed by the unusually high placebo effect in this trial, we are encouraged by the excellent overall safety profile observed in the first test of this new mechanism of action in patients with RA."  

The company intends to commence discussions with potential pharmaceutical partners to pursue further development of LX2931 in rheumatoid arthritis.

Clinical Trial

The recently completed study was a 12-week, randomized, double-blind, placebo-controlled study in 208 patients on stable dose methotrexate with progressing rheumatoid arthritis. Patients were randomized to receive either placebo (n=49) or LX2931, 70 mg (n=55), 110 mg (n=54), or 150 mg (n=50), once daily for 12 weeks.  In addition to measurements to assess the drug's safety, efficacy endpoints included the primary endpoint, ACR20 at week 12, as well as secondary endpoints of ACR20, ACR50, ACR70 and DAS28 at weeks 4, 8 and 12.  The trial was conducted at sites within the United States and Eastern Europe.

About S1P Lyase and the Role of S1P in Autoimmune Disease

S1P lyase is responsible for the irreversible degradation of S1P, a biologically active lipid that can act as a second messenger in signal transduction pathways important for immune function.  Changes in local S1P concentrations and gradients in immune tissues can modify lymphocyte migration, inflammatory cell response, and affect barrier function of endothelial cells.  Inhibiting S1P lyase results in an increase in S1P levels, primarily in lymphoid tissues.  The physiological outcome of raising S1P levels in the lymphoid system is immune-modulation, which offers new opportunities for treating autoimmune and inflammatory
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 DePuy Synthes ... with Radlink, Inc., an emerging global leader in ... guidance with its hip replacement systems. The agreement ... help improve patient outcomes, increase patient satisfaction and ... the 81st annual meeting of the American Academy ...
(Date:3/26/2015)... 2015  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... preclinical and clinical data showcasing its deep ... for Cancer Research (AACR) Annual Meeting being ... The presentations describe recent data from Merrimack,s ... as well as oral presentations on Phase ...
(Date:3/26/2015)... Kalifornien, 26. März 2015 Finesse ... die sich speziell an Innovatoren, Visionäre und ... Die zweitägige Konferenz für geladene Gäste ... im Hyatt Regency in Downtown ... Forum werden führende Akteure der Biowissenschaften die ...
Breaking Medicine Technology:DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting 2Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting 3Finesse Solutions kündigt Cellworld 2015 an 2
(Date:3/26/2015)... 26, 2015 Building off their ... medical education, the Cardiometabolic Risk Summit ... Tulane University are proud to announce a ... The interdisciplinary program , which ultimately grants ... designed for physicians, nurse practitioners, physician assistants, registered ...
(Date:3/26/2015)... Visiting Nurse Association of Northern ... gala fundraiser, Lighting the Way, Brightening the Day, on ... Madison Hotel in Morristown, NJ. , Guests will ... musician Rio Clemente, delightful cuisine, an extensive silent auction ... Additionally, two prestigious awards will be presented to this ...
(Date:3/26/2015)... 26, 2015 Dr. Alex Rabinovich and ... announce expanded offerings for Bay Area patients considering dental ... Center has long been a top-rated center, serving primarily ... to meet the strong demand by others throughout Northern ... a top-rated dental implant facility in San Francisco,”explained Dr. ...
(Date:3/26/2015)... 26, 2015 Innovative research and ... and preventing often fatal ruptures, says The Bee ... raising awareness of brain aneurysms and funding innovative ... captured national attention with the death of ... died last Friday after suffering a ruptured brain ...
(Date:3/26/2015)... The National League for Nursing, ... , has announced its partnership with Questionmark®, a ... corporations to accurately and securely measure knowledge, skills, ... Utilizing Questionmark’s state-of-the-art software and a custom-built portal, ... delivery of the seventy-five to one hundred thousand ...
Breaking Medicine News(10 mins):Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 2Health News:Research and Funding Are Keys to Raising Awareness and Ultimately Preventing Fatal Brain Aneurysm Ruptures 3Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2
... , ... ... , , , ... ...
... patient records, funded by the Wellcome Trust, suggests that older ... GPs for investigation later than younger women. Researchers ... the General Practice Research Database (GPRD) and compared recorded diagnoses ... to see whether there was a difference in how older ...
... be linked to a slight rise in high blood pressure, ... drinkers can take heart from a series of studies presented ... , For example, coffee drinkers appear to have a lower ... indication that having a few cups every day increases the ...
... ... ... , , ... ...
... , ... ... ... ...
... in front of TV, computer linked to less bonding with ... -- Too much time in front of computers or televisions ... their parents and peers, a new study suggests. , The ... 15, who provided details about how they spent their free ...
Cached Medicine News:Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 2Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 3Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 4Health News:Study finds delay in referrals for older women with ovarian cancer 2Health News:Study finds delay in referrals for older women with ovarian cancer 3Health News:Coffee Is Generally Heart-Friendly 2Health News:Coffee Is Generally Heart-Friendly 3Health News:2010 Caring Coalition Conference Welcomes Author Gail Sheehy 2Health News:2010 Caring Coalition Conference Welcomes Author Gail Sheehy 3Health News:Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009 2Health News:Screen Time May Take a Toll on Kids' Relationships 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: